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Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin
MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J,
Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward
DE, Theroux P. ACC/AHA guidelines for the management of
patients with unstable angina and non–ST-segment elevation
myocardial infarction: a report of the American College of
Cardiology/American Heart Association Task Force on Prac-
tice Guidelines (Committee on the Management of Patients
With Unstable Angina). J Am Coll Cardiol 2000;36:970 –1062.
The following errors need to be corrected:
Table 6, Page 979, “Low Risk” column, first line of first entry.
The words “or progressive” should be added to the entry after
“New-onset” to read, “New-onset or progressive CCS Class III or
IV angina in the past 2 weeks without prolonged (.20 min) rest
pain but with moderate or high likelihood of CAD (see Table 5).”
“High Risk” column, “Cardiac markers” row, first line in entry.
Delete “markedly” to read “Elevated (e.g., TnT or TnI .0.1 ng/mL).”
The corrected table with legend appears below:
Table 6. Short-Term Risk of Death or Nonfatal MI in Patients With UA*
Feature
High Risk
At least 1 of the following features
must be present:
Intermediate Risk
No high-risk feature but must have 1
of the following
Low Risk
No high- or intermediate-risk feature but
may have any of the following features:
History Accelerating tempo of ischemic
symptoms in preceding 48 h
Prior MI, peripheral or cerebrovascular
disease, or CABG, prior aspirin use
Character of
pain
Prolonged ongoing (.20 minutes)
rest pain
Prolonged (.20 min) rest angina, now
resolved, with moderate or high
likelihood of CAD
Rest angina (,20 min) or relieved
with rest or sublingual NTG
New-onset or progressive CCS Class III
or IV angina in the past 2 weeks
without prolonged (.20 min) rest pain
but with moderate or high likelihood of
CAD (see Table 5)
Clinical findings Pulmonary edema, most likely due
to ischemia
New or worsening MR murmur
S3 or new/worsening rales
Hypotension, bradycardia,
tachycardia
Age .75 years
Age .70 years
ECG Angina at rest with transient ST-
segment changes .0.05 mV
Bundle-branch block, new or
presumed new
Sustained ventricular tachycardia
T-wave inversions .0.2 mV
Pathological Q waves
Normal or unchanged ECG during an
episode of chest discomfort
Cardiac markers Elevated (e.g., TnT or TnI
.0.1 ng/mL)
Slightly elevated (e.g., TnT .0.01 but
,0.1 ng/mL)
Normal
*Estimation of the short-term risks of death and nonfatal cardiac ischemic events in UA is a complex multivariable problem that cannot be fully specified in a table such as this;
therefore, this table is meant to offer general guidance and illustration rather than rigid algorithms.
Adapted from AHCPR Clinical Practice Guideline No. 10, Unstable Angina: Diagnosis and Management, May 1994. Braunwald E, Mark DB, Jones RH, et al. Unstable
angina: diagnosis and management. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, US Public Health Service,
US Department of Health and Human Services; 1994; AHCPR Publication No. 94-0602.
Table 11, Page 995, “Dose/Dosage” column, entry for intravenous
nitroglycerin. Replace mg/min with mg/min to read 5–200 mg/min.
The corrected table with legend appears below:
Table 11. NTG and Nitrates in Angina
Compound Route Dose/Dosage Duration of Effect
NTG Sublingual tablets
Spray
Transdermal
Intravenous
0.3–0.6 mg up to 1.5 mg
0.4 mg as needed
0.2–0.8 mg/h every 12 h
5–200 mg/min
1–7 minutes
Similar to sublingual tablets
8–12 h during intermittent
therapy
Tolerance in 7–8 h
Isosorbide dinitrate Oral
Oral, slow release
5–80 mg, 2 or 3 times daily
40 mg 1 or 2 times daily
Up to 8 h
Up to 8 h
Isosorbide mononitrate Oral
Oral, slow release
20 mg twice daily
60–240 mg once daily
12–24 h
Pentaerythritol tetranitrate Sublingual 10 mg as needed Not known
Erythritol tetranitrate Sublingual
Oral
5–10 mg as needed
10–30 mg 3 times daily
Not known
Not known
Adapted from Table 28 in Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina. J Am Coll
Cardiol 1999;33:2092–197.
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Page 1006, first column, 2nd paragraph, 6th line. Delete the word
“reduced” and the word dalteparin should be substituted for the
word enoxaparin (7th line).
The full paragraph should read:
The FRISC, FRIC, TIMI 11B, and Fast Revascularization
During Instability in Coronary Artery Disease (FRISC II)
trials evaluated the potential benefit of the prolonged
administration of an LMWH after hospital discharge. The
first 3 of these trials did not show a benefit of treatment
beyond the acute phase. In the FRISC trial, doses of
dalteparin were administered between 6 days and 35 to 45
days; in FRIC, patients were rerandomized after the initial
6-day treatment period to receive dalteparin for an addi-
tional 40 days; and the outpatient treatment period lasted 5
to 6 weeks in TIMI 11B and 1 week in the FRAXIS trial.
The FRISC II trial used a different study design. Dalteparin
was administered to all patients for a minimum of 5 days
(223). Patients were subsequently randomized to receive
placebo or the continued administration of dalteparin twice
a day for up to 90 days. Analysis of the results from the time
of randomization showed a significant reduction with dalte-
parin in the composite end point of death or MI at 30 days
(3.1% vs. 5.9%, p 5 0.002) but not at 3 months (6.7% vs.
8.0%, p 5 0.17). The composite of death, MI, or revascu-
larization during the total treatment period was reduced at
3 months (29.1% vs. 33.4%, p 5 0.031). The benefits of
prolonged dalteparin administration were limited to pa-
tients who were managed medically and to patients with
elevated TnT levels at baseline. These results may make a
case for the prolonged use of an LMWH in selected
patients who are managed medically or in whom angiogra-
phy is delayed.
Figure 10, Page 1009, first column, “All” graph. “3.9%” should be
changed to “2.9%.”
The corrected figure with legend appears below:
Figure 10. Kaplan-Meier curves showing cumulative incidence of death or MI in patients randomly assigned to platelet GP IIb/IIIa receptor antagonist
(bold line) or placebo. Data are derived from the CAPTURE, PURSUIT, and PRISM-PLUS trials (248). Left, Events during the initial period of medical
treatment until the moment of PCI or CABG. In the CAPTURE trial, abciximab was administered for 18 to 24 h before the PCI was performed in almost
all patients as per study design; abciximab was discontinued 1 h after the intervention. In PURSUIT, a PCI was performed in 11.2% of patients during
a period of medical therapy with eptifibatide that lasted 72 h and for 24 h after the intervention. In PRISM-PLUS, an intervention was performed in 30.2%
of patients after a 48-h period of medical therapy with tirofiban, and the drug infusion was maintained for 12 to 24 h after an intervention. Right, Events
occurring at the time of PCI and the next 48 h, with the event rates reset to 0% before the intervention. CK or CK-MB elevations exceeding 2 times the
upper limit of normal were considered as infarction during medical management and exceeding 3 times the upper limit of normal for PCI-related events.
Adapted from Boersma et al. (248), CAPTURE (182), PURSUIT (10), and PRISM-PLUS (21).
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